REC Share Price

Open 24.85 Change Price %
High 25.32 1 Day 0.40 1.61
Low 24.59 1 Week -0.25 -0.98
Close 25.21 1 Month -0.42 -1.64
Volume 685291 1 Year 2.41 10.57
52 Week High 29.74
52 Week Low 19.08
REC Important Levels
Resistance 2 25.89
Resistance 1 25.61
Pivot 25.04
Support 1 24.81
Support 2 24.53
BIT Italy Most Active Stocks
PMI 0.31 -3.12%
PMI 0.31 -3.12%
ISP 2.13 -0.47%
TIT 0.72 1.41%
UCG 2.08 0.00%
SPM 0.42 -4.55%
SPM 0.42 -4.55%
ENEL 3.83 1.06%
BP 1.99 -0.50%
BP 1.99 -0.50%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
CTIC 0.47 17.50%
CTIC 0.47 17.50%
MIC 4.31 7.75%
MIC 4.31 7.75%
MIC 4.31 7.75%
MIC 4.31 7.75%
More..
BIT Italy Top Losers Stocks
PR 0.04 -20.00%
PR 0.04 -20.00%
STEF 0.09 -10.00%
IIN 0.11 -8.33%
IIN 0.11 -8.33%
IIN 0.11 -8.33%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
More..

Recordati (BIT: REC)

REC Technical Analysis 2
As on 2nd Dec 2016 REC Share Price closed @ 25.21 and we RECOMMEND Buy for LONG-TERM with Stoploss of 25.12 & Strong Sell for SHORT-TERM with Stoploss of 26.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
REC Target for December
1st Target up-side 27.15
2nd Target up-side 28.15
3rd Target up-side 29.15
1st Target down-side 24.31
2nd Target down-side 23.31
3rd Target down-side 22.31
REC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.recordati.com
REC Address
REC
Via Matteo Civitali 1
Milano, MI 20148
Italy
Phone: 39 02 487871
Fax: 39 02 40 07 37 47
REC Latest News
RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2016. CONTINUED GROWTH ...   GlobeNewswire (press release)   - 27th Oct 16
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...   GlobeNewswire (press release)   - 06th Sep 16
Deals Rumor Mill: Hewlett Packard, Recordati, Old Mutual   Law360 (subscription)   - 02nd Aug 16
Italy's Recordati Said to Weigh Options Amid Asian Interest   Bloomberg   - 01st Aug 16
RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES ...   GlobeNewswire (press release)   - 28th Jul 16
Recordati rises across 1st-qtr financial results   The Pharma Letter (registration)   - 05th May 16
RECORDATI: SHAREHOLDERS APPROVE 2015 ACCOUNTS. DIVIDEND EU 0.60 PER SHARE (+20 ...   GlobeNewswire (press release)   - 13th Apr 16
Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a ...   GlobeNewswire (press release)   - 19th Aug 15
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...   GlobeNewswire (press release)   - 06th May 15
Apricus and Recordati Sign Exclusive License Agreement to Market Topical ...   GlobeNewswire (press release)   - 10th Feb 14
Interactive Technical Analysis Chart Recordati ( REC BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Recordati
REC Business Profile
Recordati S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including antibiotics and antivirals, cardiovascular, central nervous system, dermatological, gastroenterology, genito-urinary system, muscolo-skeletal disorders and pain therapy, and obstetics and gynaecology; and non-prescription pharmaceuticals. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. Its products also include Zanipress/Zanitek, a combination of lercanidipine and enalapril for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Lercanidipine/enalapril fixed combination, which is in pre-registration stage for the treatment of essential hypertension. In addition, it offers gastroenterological drugs, oral rehydration products, probiotics, and OTC brands for gynecological use. Its products under Phase II clinical trials include Cystadrops for the treatment of ocular cystinosis, and REC 0422 to treat overactive bladder and incontinence; and Phase I clinical trials comprise REC 1819 for the treatment of overactive bladder and incontinence, and REC 0438 to treat overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.